Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Aclaris Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Aclaris Therapeutics, Inc.

ACRS

Aclaris Therapeutics, Inc.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel small and large molecule therapies for immuno-inflammatory diseases. Utilizing its proprietary KINect drug discovery platform, Aclaris advances biologics and kinase inhibitor candidates targeting validated pathways. Its pipeline includes monoclonal and bispecific antibodies, oral kinase inhibitors, and topical treatments. The company serves patients with unmet medical needs through research, development, and strategic partnerships, relying on third-party manufacturing and regulatory approvals.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Aclaris Therapeutics, Inc.

1
1
Aclaris Therapeutics, Inc. Aclaris Therapeutics Reports 37% Revenue Growth but Increased Net Loss in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Aclaris Therapeutics, Inc. Aclaris Therapeutics Reports $64.9 Million Net Loss and $7.8 Million Revenue in Annual Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Aclaris Therapeutics, Inc. Aclaris Therapeutics Reports $45.1 Million Net Loss and Decreased Revenue for Nine Months Ended September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Aclaris Therapeutics, Inc. Aclaris Therapeutics Reports 36% Revenue Decline and $15.4 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Aclaris Therapeutics, Inc. Aclaris Therapeutics Reports $1.5 Million Revenue in Q1 2025, 39% Decline Year-Over-Year

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Aclaris Therapeutics, Inc. Aclaris Therapeutics Reports $132.1 Million Net Loss and Revenue Decline for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Aclaris Therapeutics, Inc. Aclaris Therapeutics Reports Decline in Revenue, Improved Operational Efficiency in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments